Angeli's Salt, a nitroxyl anion donor, reverses endothelin-1 mediated vascular dysfunction in murine aorta

Brandi M. Wynne, Hicham Labazi, Zidonia N. Carneiro, Rita C. Tostes, R Clinton Webb

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Nitroglycerin (Gtn) is a treatment for cardiovascular patients due to its vasodilatory actions, but induces tolerance when given chronically. A proposed mechanism is the superoxide (O2-)-oxidative stress hypothesis, which suggests that Gtn increases O2- production. Nitric oxide (NO) exists in three different redox states; the protonated, reduced state, nitroxyl anion (HNO) is an emerging candidate in vascular regulation. HNO is resistant to scavenging and of particular interest in conditions where high levels of reactive oxygen species (ROS) exist. We hypothesize that treatment with Gtn will exacerbate endothelin 1 (ET-1) induced vascular dysfunction via an increase in ROS, while treatment with Angeli's Salt (AS), an HNO donor, will not. Aorta from mice were isolated and divided into four groups: vehicle, ET-1 [0.1 μM, 1 μM], ET-1+Gtn [Gtn 1 μM] and ET-1+AS [AS 1 μM]. Concentration response curves (CRCs) to acetylcholine (ACh) and phenylephrine (Phe) were performed. Aorta incubated with ET-1 (for 20–22 h) exhibited a decreased relaxation response to ACh and an increase in Phe-mediated contraction. Aorta incubated with AS exhibited a reversal in ET-1 induced vascular and endothelial dysfunction. ET-1 increased ROS in aortic vascular smooth muscle cells (VSMCs), visualized by dihydroethidium (DHE) staining. AS incubated reduced this ROS generation, yet maintained with Gtn treatment. These data suggest that aorta incubated with the HNO donor, AS, can reverse ET-1 mediated vascular dysfunction, which may be through a decrease or prevention of ROS generation. We propose that HNO may be vasoprotective and that HNO donors studied as a therapeutic option where other organic nitrates are contraindicative.

Original languageEnglish (US)
Pages (from-to)294-301
Number of pages8
JournalEuropean Journal of Pharmacology
Volume814
DOIs
StatePublished - Nov 5 2017

Fingerprint

Endothelin-1
Anions
Blood Vessels
Aorta
Reactive Oxygen Species
Phenylephrine
Acetylcholine
Tissue Donors
Therapeutics
oxyhyponitrite
nitroxyl
Nitroglycerin
Vascular Smooth Muscle
Superoxides
Nitrates
Oxidation-Reduction
Smooth Muscle Myocytes
Nitric Oxide
Oxidative Stress
Staining and Labeling

Keywords

  • Angeli's Salt
  • Endothelin-1
  • HNO
  • Nitroglycerin
  • Vascular dysfunction

ASJC Scopus subject areas

  • Pharmacology

Cite this

Angeli's Salt, a nitroxyl anion donor, reverses endothelin-1 mediated vascular dysfunction in murine aorta. / Wynne, Brandi M.; Labazi, Hicham; Carneiro, Zidonia N.; Tostes, Rita C.; Webb, R Clinton.

In: European Journal of Pharmacology, Vol. 814, 05.11.2017, p. 294-301.

Research output: Contribution to journalArticle

Wynne, Brandi M. ; Labazi, Hicham ; Carneiro, Zidonia N. ; Tostes, Rita C. ; Webb, R Clinton. / Angeli's Salt, a nitroxyl anion donor, reverses endothelin-1 mediated vascular dysfunction in murine aorta. In: European Journal of Pharmacology. 2017 ; Vol. 814. pp. 294-301.
@article{7e52a6bf2b6642eea3b536fa0aee6a2f,
title = "Angeli's Salt, a nitroxyl anion donor, reverses endothelin-1 mediated vascular dysfunction in murine aorta",
abstract = "Nitroglycerin (Gtn) is a treatment for cardiovascular patients due to its vasodilatory actions, but induces tolerance when given chronically. A proposed mechanism is the superoxide (O2-)-oxidative stress hypothesis, which suggests that Gtn increases O2- production. Nitric oxide (NO) exists in three different redox states; the protonated, reduced state, nitroxyl anion (HNO) is an emerging candidate in vascular regulation. HNO is resistant to scavenging and of particular interest in conditions where high levels of reactive oxygen species (ROS) exist. We hypothesize that treatment with Gtn will exacerbate endothelin 1 (ET-1) induced vascular dysfunction via an increase in ROS, while treatment with Angeli's Salt (AS), an HNO donor, will not. Aorta from mice were isolated and divided into four groups: vehicle, ET-1 [0.1 μM, 1 μM], ET-1+Gtn [Gtn 1 μM] and ET-1+AS [AS 1 μM]. Concentration response curves (CRCs) to acetylcholine (ACh) and phenylephrine (Phe) were performed. Aorta incubated with ET-1 (for 20–22 h) exhibited a decreased relaxation response to ACh and an increase in Phe-mediated contraction. Aorta incubated with AS exhibited a reversal in ET-1 induced vascular and endothelial dysfunction. ET-1 increased ROS in aortic vascular smooth muscle cells (VSMCs), visualized by dihydroethidium (DHE) staining. AS incubated reduced this ROS generation, yet maintained with Gtn treatment. These data suggest that aorta incubated with the HNO donor, AS, can reverse ET-1 mediated vascular dysfunction, which may be through a decrease or prevention of ROS generation. We propose that HNO may be vasoprotective and that HNO donors studied as a therapeutic option where other organic nitrates are contraindicative.",
keywords = "Angeli's Salt, Endothelin-1, HNO, Nitroglycerin, Vascular dysfunction",
author = "Wynne, {Brandi M.} and Hicham Labazi and Carneiro, {Zidonia N.} and Tostes, {Rita C.} and Webb, {R Clinton}",
year = "2017",
month = "11",
day = "5",
doi = "10.1016/j.ejphar.2017.08.024",
language = "English (US)",
volume = "814",
pages = "294--301",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",

}

TY - JOUR

T1 - Angeli's Salt, a nitroxyl anion donor, reverses endothelin-1 mediated vascular dysfunction in murine aorta

AU - Wynne, Brandi M.

AU - Labazi, Hicham

AU - Carneiro, Zidonia N.

AU - Tostes, Rita C.

AU - Webb, R Clinton

PY - 2017/11/5

Y1 - 2017/11/5

N2 - Nitroglycerin (Gtn) is a treatment for cardiovascular patients due to its vasodilatory actions, but induces tolerance when given chronically. A proposed mechanism is the superoxide (O2-)-oxidative stress hypothesis, which suggests that Gtn increases O2- production. Nitric oxide (NO) exists in three different redox states; the protonated, reduced state, nitroxyl anion (HNO) is an emerging candidate in vascular regulation. HNO is resistant to scavenging and of particular interest in conditions where high levels of reactive oxygen species (ROS) exist. We hypothesize that treatment with Gtn will exacerbate endothelin 1 (ET-1) induced vascular dysfunction via an increase in ROS, while treatment with Angeli's Salt (AS), an HNO donor, will not. Aorta from mice were isolated and divided into four groups: vehicle, ET-1 [0.1 μM, 1 μM], ET-1+Gtn [Gtn 1 μM] and ET-1+AS [AS 1 μM]. Concentration response curves (CRCs) to acetylcholine (ACh) and phenylephrine (Phe) were performed. Aorta incubated with ET-1 (for 20–22 h) exhibited a decreased relaxation response to ACh and an increase in Phe-mediated contraction. Aorta incubated with AS exhibited a reversal in ET-1 induced vascular and endothelial dysfunction. ET-1 increased ROS in aortic vascular smooth muscle cells (VSMCs), visualized by dihydroethidium (DHE) staining. AS incubated reduced this ROS generation, yet maintained with Gtn treatment. These data suggest that aorta incubated with the HNO donor, AS, can reverse ET-1 mediated vascular dysfunction, which may be through a decrease or prevention of ROS generation. We propose that HNO may be vasoprotective and that HNO donors studied as a therapeutic option where other organic nitrates are contraindicative.

AB - Nitroglycerin (Gtn) is a treatment for cardiovascular patients due to its vasodilatory actions, but induces tolerance when given chronically. A proposed mechanism is the superoxide (O2-)-oxidative stress hypothesis, which suggests that Gtn increases O2- production. Nitric oxide (NO) exists in three different redox states; the protonated, reduced state, nitroxyl anion (HNO) is an emerging candidate in vascular regulation. HNO is resistant to scavenging and of particular interest in conditions where high levels of reactive oxygen species (ROS) exist. We hypothesize that treatment with Gtn will exacerbate endothelin 1 (ET-1) induced vascular dysfunction via an increase in ROS, while treatment with Angeli's Salt (AS), an HNO donor, will not. Aorta from mice were isolated and divided into four groups: vehicle, ET-1 [0.1 μM, 1 μM], ET-1+Gtn [Gtn 1 μM] and ET-1+AS [AS 1 μM]. Concentration response curves (CRCs) to acetylcholine (ACh) and phenylephrine (Phe) were performed. Aorta incubated with ET-1 (for 20–22 h) exhibited a decreased relaxation response to ACh and an increase in Phe-mediated contraction. Aorta incubated with AS exhibited a reversal in ET-1 induced vascular and endothelial dysfunction. ET-1 increased ROS in aortic vascular smooth muscle cells (VSMCs), visualized by dihydroethidium (DHE) staining. AS incubated reduced this ROS generation, yet maintained with Gtn treatment. These data suggest that aorta incubated with the HNO donor, AS, can reverse ET-1 mediated vascular dysfunction, which may be through a decrease or prevention of ROS generation. We propose that HNO may be vasoprotective and that HNO donors studied as a therapeutic option where other organic nitrates are contraindicative.

KW - Angeli's Salt

KW - Endothelin-1

KW - HNO

KW - Nitroglycerin

KW - Vascular dysfunction

UR - http://www.scopus.com/inward/record.url?scp=85028695168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028695168&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2017.08.024

DO - 10.1016/j.ejphar.2017.08.024

M3 - Article

VL - 814

SP - 294

EP - 301

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

ER -